NCT01966107: A reported trial by AstraZeneca
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01966107 |
|---|---|
| Title | Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Oct. 16, 2013 |
| Completion date | Sept. 21, 2017 |
| Required reporting date | Sept. 21, 2018, midnight |
| Actual reporting date | Sept. 19, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |